The promise of personalized medicine to deliver "the right treatments at the right time to the right person" is the next frontier in healthcare. However, to implement personalized medicine in chronic diseases such as diabetes mellitus and diabetic kidney disease (DKD), a number of different aspects need to be taken into account. Better risk stratification and more precise options for treatment need to be developed and included in clinical practice guidelines. A patient's unique psychological, social and environmental situation also drive disease progression and outcomes.
Appraising the cost effectiveness of precision medicines is necessary, not just as the cost of new therapies, but also the cost of diagnosis with novel methodologies and averted complications. As the prevalence of DKD grows worldwide to epidemic proportions, challenges such as global disparities in resources, access to healthcare and prevalence need to be addressed. This review considers these issues to achieve the short and longer-term goals of implementing personalized medicine in clinical practice.
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| INTRODUCTION
Diabetes mellitus, and especially type 2 diabetes, will be the seventh leading cause of mortality by 2030. 1 Diabetic kidney disease (DKD), a complication of diabetes, is the most common cause of end-stage renal disease (ESRD) both in the developed and the developing world and accounts for 20% to 40% of patients starting renal replacement therapy. 2 Often diabetes and DKD are coupled with hypertension and cardiovascular disease. Conventional treatment paradigms target risk factors separately whereas comorbidities are not necessarily independent of each other.
Over the last decades, there has been clear progress in assessing risk factors and controlling diabetes. Subsequently, the prognosis of patients with diabetes has gradually improved. 1 Nonetheless, mortality, when compared to the general population, is higher, and the risk is especially high in patients with impaired renal function. Many reasons for the morbidity and mortality in DKD have been identified, including suboptimal application of evidence-based therapies (eg, due to lack of medication intensification by physicians or insufficient lifestyle changes or medication adherence by patients), and variability in response to medication (eg, inadequate efficacy of therapy even when optimally applied, or genetic differences, leading to differential treatment response). Additionally, a general lack of understanding of the true pathobiology of DKD results in the treatment of symptoms and diagnostic labels instead of a focus on causes and mechanisms. This inefficiency results in many patients not being properly treated or not receiving the maximum benefit possible for the multitude of treatment modalities available. In order to improve the situation, a shift towards care of the individual patient is needed, rather than for the particular manifestation of the disease.
Individualized medicine is a medical model that proposes the customization of healthcare-with medical decisions, practices and/or products being tailored to the individual patient. Ultimately, this medical model aims to improve patient care and achieve better outcomes, all while providing a more cost effective healthcare system. Chronic diseases like diabetes will cost the global economy $47 trillion over the next 20 years. DKD additionally places a huge economic burden on the healthcare system. The overall costs of care for people with DKD are extraordinarily high, due in large part to the strong relationship of DKD with cardiovascular disease and development of ESRD. 3 The total annual cost to the National Health Service (NHS) in the United Kingdom was £685 million ($1.5 billion), 4 and the overall Medicare expenditures for diabetes and chronic kidney disease (CKD) in the mostly older (≥65 years of age) US Medicare population were approximately $25 billion in 2011. 3 In view of these enormous costs of DKD, identifying strategies for better cost-benefit is in the best interest of patients and society.
In this article, we highlight different aspects that need to be taken 6 These findings should modify our approach to DKD in general, recognizing that the variability of the disease should be taken into account when choosing therapy.
Currently, evidence for these guidelines is based on the effect of drugs on clinical outcomes on populations included in clinical trials rather than based on individuals. For example, in the TREAT study, patients with DKD and anemia were randomly assigned to darbepoetin alfa to achieve a hemoglobin level of 13 g/dL or to rescue erythropoiesis stimulating agent (ESA) therapy in case hemoglobin levels dropped to less than 9.0 g/dL. Active therapy did not reduce the risk of either of the two primary composite outcomes (death or a cardiovascular event or death or a renal event) but was associated with an increased risk of stroke. 7 These results were in line with several other studies, [8] [9] [10] and based on this evidence, the Kidney Disease: Improving Global Outcomes (KDIGO) guideline group recommended that in adult patients, ESAs must not be used to intentionally increase hemoglobin above 13 g/dL (graded evidence level 1A). 11 ARBs with direct renin inhibitors should not be used. 15 This recommendation is based on evidence that the risk of hyperkalaemia and/or acute kidney injury is increased with these combinations when compared to others. 16 Nonetheless Palmer et al showed in the same meta-analysis that double blockade of the renin-angiotensinaldosterone system is the most efficient way to lower proteinuria and the risk of terminal end stage renal failure in patients with diabetes. 16 Thus, if we could apply individualized medicine tools to identify the population at highest risk of side effects, an optimal approach of multiple-drug antihypertensive and albuminuria lowering therapy in clinical practice could be individualized.
| IMPLEMENTING PERSONALIZED MEDICINE: THE PATIENT'S PERSPECTIVE
Individualized medicine tries to incorporate all aspects of a person's disease and response to treatment and identify the treatment that will result in the optimal outcome for the individual patient. In order to achieve this, individualized medicine focuses on an individual's unique biological characteristics to tailor diagnostics and therapeutics to that specific patient, by utilizing biological -omics techniques, that is, genomics, proteomics, metabolomics, epigenomics and pharmacogenomics. In the past decade, a huge number of literature has been pub- given health condition will manifest in that person and how that condition will respond to treatment. 21 Not every patient has the same values in life and people might make different choices in remarkably similar situations. Importantly as well, the environment and society the person is in, as well as the resources available, will also have important roles in disease progression.
| A patient's viewpoint and concerns for personalized medicine
Engaging patients and educating patients in order to advance personalized medicine is crucial. The clinical and research community asks a lot from patients, namely time and accepting of risks in exchange for hope of better treatment options and outcomes.
Patients often say that they want hope and value innovation and exploration. 22 Patients will and do give their time for research, with full awareness that they may not personally benefit from it. With the potential benefits of personal medicine come issues for patients as well. Personal privacy may become an area of concern.
The genetic research and testing needed for personalized medicine reveals information that patients may not want to know or be disclosed. Researchers and clinicians need to treat patients' data with utmost care, and must be transparent on how data will be used to avoid public loss of trust. Furthermore, retaining realism and honesty on when and if personalized medicine tools will reach the patient, and their affordability needs to be addressed. Stakeholders in personalized medicine need to take a good look at patient-research priorities and get better at explaining, following-up and valuing patient input.
| IMPLEMENTING PERSONALIZED MEDICINE: THE PAYER'S PERSPECTIVE
Personalized medicine encompasses therapies targeted at patients most likely to benefit. Providing these drugs requires regulatory approval granting marketing authorization but also (for healthcare systems funded by tax-payers) evidence that these therapies work better or as well as existing therapies, and reflect good value for money. 
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